Pfizer (NYSE:PFE) Shares Down 1.1% – Time to Sell?

Shares of Pfizer Inc. (NYSE:PFE) fell 1.1% during mid-day trading on Tuesday . The stock traded as low as $25.81 and last traded at $25.85. 8,437,133 shares were traded during mid-day trading, a decline of 77% from the average session volume of 36,645,983 shares. The stock had previously closed at $26.14.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

The company has a market cap of $144.82 billion, a PE ratio of 18.12, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a 50-day simple moving average of $26.15 and a 200 day simple moving average of $27.02.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Hedge Funds Weigh In On Pfizer

Several large investors have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.